Please login to the form below

Not currently logged in

Merck Serono pushes into immunotherapies for cancer

Pharma company sets up dedicated R&D unit
Merck Serono Geneva HQ

Merck Serono has set up a dedicated R&D unit to seek out new therapies that stimulate a patient's own immune system to fight cancer.

The company said the new unit would complement its established work in oncology by bringing together research, early development work and biomarker strategies for immunological therapies.

The unit will focus on three main areas of research, namely the development of therapeutic cancer vaccines, targeting cancer stem cell to stop tumours forming or spreading, and eliminating or circumventing inhibitory mechanisms in the immune system that prevent cancer cells from being recognised and attacked by the body.

Merck Serono's announcement comes shortly after analyst Andrew Baum at investment bank Citigroup published a report predicting that immunotherapies will become the dominant force in cancer treatment in the next decade, accounting for around 60 per cent of the oncology treatment market and generating $35bn a year.

The meteoric rise of these therapies stems from the fact that they are taken over an extended period of time, command premium pricing and will likely show significant efficacy gains over current treatment approaches.

One of the early entrants into the category - Bristol-Myers Squibb's Yervoy (ipilimumab) for melanoma - matches that profile and posted sales up 47 per cent to $706m in 2012, its first full-year on the market after debuting in the US in March 2011.

To tap into that potential, Merck Serono says it has assembled a team of researchers and clinicians who will try to build a portfolio of cancer immunotherapies both in-house and in collaboration with external groups.

"The complexity of cancer requires diverse approaches that will enable alternative therapeutic interventions," said the company's head of early-stage R&D Bernhard Kirschbaum.

The unit launches with several projects in phase I clinical and preclinical testing, including a monoclonal antibody against programmed Death-Ligand 1 (PD-L1) the same target as Roche's MPDL3280A, for which early-stage clinical trial results were presented last month at the American Society of Clinical Oncology (ASCO) annual meeting.

Also highlighted by Merck Serono are two antibodies against interleukin-12 (IL-12) and IL-2 that target the necrotic centre of tumours, region that generally proves highly-resistant to conventional chemotherapy.

"Our goal is to develop leading immunotherapies that work in combination with other therapeutic modalities, understanding that attacking multiple cancer targets simultaneously increases the possibility of therapeutic success," said Helen Sabzevari, who will lead the new immuno-oncology unit.

27th June 2013

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...